(Q61624856)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563856%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563856%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

main subject

phase II clinical trial

1 reference

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563856%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Janell Seeger

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563856%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Norman Wolmark

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563856%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Sheri K Dennison

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563856%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Samuel A Jacobs

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563856%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

John W Wilson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563856%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Terrence P Cescon

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563856%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Jane M Raymond

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563856%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Charles E Geyer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563856%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

12 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563856%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

31 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563856%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563856%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563856%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

545-551

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17563856%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-007-9055-6

31 December 2019

exact match

0 references

cites work

Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor

1 reference

12 December 2020

Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations

1 reference

12 December 2020

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

1 reference

12 December 2020

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

1 reference

12 December 2020

Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies

1 reference

12 December 2020

The role of EGFR-directed therapy in the treatment of breast cancer

1 reference

12 December 2020

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

1 reference

12 December 2020

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

1 reference

12 December 2020

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial.

1 reference

12 December 2020

Docetaxel for treatment of solid tumours: a systematic review of clinical data

1 reference

12 December 2020

Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination

1 reference

12 December 2020

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

1 reference

12 December 2020

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

1 reference

12 December 2020

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

12 December 2020

The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study

1 reference

12 December 2020

Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000

1 reference

12 December 2020

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

1 reference

12 December 2020

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

1 reference

12 December 2020

Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes

1 reference

12 December 2020

Novel targets for lung cancer therapy: part II.

1 reference

12 December 2020

Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

1 reference

12 December 2020

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

1 reference

12 December 2020

Overview of tyrosine kinase inhibitors in clinical breast cancer.

1 reference

12 December 2020

The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients

1 reference

12 December 2020

Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up

1 reference

12 December 2020

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

12 December 2020

Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer

1 reference

12 December 2020

Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value?

1 reference

12 December 2020

[Inhibition of tumor neo-angiogenesis and induction of apoptosis as properties of docetaxel (taxotere)]

1 reference

12 December 2020